User menu

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Bibliographic reference Heymans, Stephane ; Hirsch, Emilio ; Anker, stefan D. ; Aukrust, Pal ; Cohen-Tervaert, Jan W. ; et. al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.. In: European journal of heart failure, Vol. 11, no. 2, p. 129 (2009)
Permanent URL http://hdl.handle.net/2078.1/81757
  1. Schocken D. D., Benjamin E. J., Fonarow G. C., Krumholz H. M., Levy D., Mensah G. A., Narula J., Shor E. S., Young J. B., Hong Y., Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group, 10.1161/circulationaha.107.188965
  2. Alla François, Zannad Faiez, Filippatos Gerasimos, Epidemiology of acute heart failure syndromes, 10.1007/s10741-007-9009-2
  3. Rauchhaus M., Doehner W., Francis D. P., Davos C., Kemp M., Liebenthal C., Niebauer J., Hooper J., Volk H.-D., Coats A. J. S., Anker S. D., Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure, 10.1161/01.cir.102.25.3060
  4. Deswal, Circulation, 103, 2055 (2001)
  5. Mann Douglas L., Targeted Anticytokine Therapy and the Failing Heart, 10.1016/j.amjcard.2005.03.007
  6. Gullestad Lars, Aukrust Pål, Review of Trials in Chronic Heart Failure Showing Broad-Spectrum Anti-Inflammatory Approaches, 10.1016/j.amjcard.2005.03.008
  7. Chung E. S., Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor- , in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial, 10.1161/01.cir.0000077913.60364.d2
  8. Mann D. L., Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), 10.1161/01.cir.0000124490.27666.b2
  9. Frantz S., Bauersachs J., Ertl G., Post-infarct remodelling: contribution of wound healing and inflammation, 10.1093/cvr/cvn292
  10. Frangogiannis Nikolaos, Targeting the Inflammatory Response in Healing Myocardial Infarcts, 10.2174/092986706777585086
  11. Mann D. L., Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future, 10.1161/01.res.0000043825.01705.1b
  12. Anker Stefan D., Coats Andrew J.S., How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH, 10.1016/s0167-5273(02)00470-9
  13. Aukrust Pål, Ueland Thor, Lien Egil, Bendtzen Klaus, Müller Fredrik, Andreassen Arne K, Nordøy Ingvild, Aass Halfdan, Espevik Terje, Simonsen Svein, Frøland Stig S, Gullestad Lars, Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, 10.1016/s0002-9149(98)00872-8
  14. Kapadia Samir, Dibbs Ziad, Kurrelmeyer Karla, Kalra Dinesh, Seta Yukihiro, Wang Feng, Bozkurt Biykem, Oral Hakan, Sivasubramanian Natarajan, Mann Douglas L., THE ROLE OF CYTOKINES IN THE FAILING HUMAN HEART, 10.1016/s0733-8651(05)70041-2
  15. Heymans, Nat Med, 5, 1135 (1999)
  16. Jugdutt Bodh, Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets, 10.2174/138945008783954934
  17. Patten, Am J Physiol, 274, H1812 (1998)
  18. Lutgens E, Chronic myocardial infarction in the mouse: cardiac structural and functional change, 10.1016/s0008-6363(98)00216-8
  19. Rohde, Circulation, 99, 3063 (1999)
  20. Hayashidani Shunji, Tsutsui Hiroyuki, Ikeuchi Masaki, Shiomi Tetsuya, Matsusaka Hidenori, Kubota Toru, Imanaka-Yoshida Kyoko, Itoh Takeshi, Takeshita Akira, Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction, 10.1152/ajpheart.00207.2003
  21. Cleutjens Jack P.M., Creemers Esther E.J.M., Integration of concepts: Cardiac extracellular matrix remodeling after myocardial infarction, 10.1054/jcaf.2002.129261
  22. Carmeliet P., Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., Dyspersin G.D., Cleutjens J.P.M., Shipley M., Angellilo A., Levi M., Nüβe O., Baker A., Keshet E., Lupu F., Herbert J-M, Smits J.F.M., Shapiro S.D., Baes M., Borgers M., Collen D., Daemen M. J.A.P., 10.1038/13459
  23. Ohta K., Elafin-overexpressing mice have improved cardiac function after myocardial infarction, 10.1152/ajpheart.00479.2002
  24. Frangogiannis N. G., Critical Role of Endogenous Thrombospondin-1 in Preventing Expansion of Healing Myocardial Infarcts, 10.1161/circulationaha.104.510354
  25. Krishnamurthy P, Deficiency of  1 integrins results in increased myocardial dysfunction after myocardial infarction, 10.1136/hrt.2005.071001
  26. Mason J, Myocarditis and dilated cardiomyopathy An inflammatory link, 10.1016/s0008-6363(03)00437-1
  27. Pauschinger Matthias, Chandrasekharan Kumaran, Noutsias Michel, K�hl Uwe, Schwimmbeck Lothar Peter, Schultheiss Heinz-Peter, Viral heart disease: molecular diagnosis, clinical prognosis, and treatment strategies, 10.1007/s00430-003-0213-y
  28. Bowles Neil E, Ni Jiyuan, Kearney Debra L, Pauschinger Matthias, Schultheiss Heinz-Peter, McCarthy Robert, Hare Joshua, Bricker J.Timothy, Bowles Karla R, Towbin Jeffrey A, Detection of viruses in myocardial tissues by polymerase chain reaction, 10.1016/s0735-1097(03)00648-x
  29. Pankuweit S., Parvovirus B19 Genome in Endomyocardial Biopsy Specimen, 10.1161/01.cir.0000124881.00415.59
  30. Kuhl U., Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction, 10.1161/circulationaha.105.548156
  31. Mahrholdt H., Wagner A., Deluigi C. C., Kispert E., Hager S., Meinhardt G., Vogelsberg H., Fritz P., Dippon J., Bock C. -T., Klingel K., Kandolf R., Sechtem U., Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis, 10.1161/circulationaha.105.606509
  32. Caforio A. L.P., Calabrese F., Angelini A., Tona F., Vinci A., Bottaro S., Ramondo A., Carturan E., Iliceto S., Thiene G., Daliento L., A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis, 10.1093/eurheartj/ehm076
  33. Kuhl U., High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With "Idiopathic" Left Ventricular Dysfunction, 10.1161/01.cir.0000155616.07901.35
  34. Tschope C., High Prevalence of Cardiac Parvovirus B19 Infection in Patients With Isolated Left Ventricular Diastolic Dysfunction, 10.1161/01.cir.0000155615.68924.b3
  35. Andréoletti Laurent, Ventéo Lydie, Douche-Aourik Fatima, Canas Frédéric, de la Grandmaison Geoffroy Lorin, Jacques Jérôme, Moret Hélène, Jovenin Nicolas, Mosnier Jean-François, Matta Mathieu, Duband Sébastien, Pluot Michel, Pozzetto Bruno, Bourlet Thomas, Active Coxsackieviral B Infection Is Associated With Disruption of Dystrophin in Endomyocardial Tissue of Patients Who Died Suddenly of Acute Myocardial Infarction, 10.1016/j.jacc.2007.07.080
  36. Mahrholdt H., Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology, 10.1161/01.cir.0000118493.13323.81
  37. Xiong D., Yajima T., Lim B.-K., Stenbit A., Dublin A., Dalton N. D., Summers-Torres D., Molkentin J. D., Duplain H., Wessely R., Chen J., Knowlton K. U., Inducible Cardiac-Restricted Expression of Enteroviral Protease 2A Is Sufficient to Induce Dilated Cardiomyopathy, 10.1161/circulationaha.106.631093
  38. Maekawa Y., Ouzounian M., Opavsky M. A., Liu P. P., Connecting the Missing Link Between Dilated Cardiomyopathy and Viral Myocarditis: Virus, Cytoskeleton, and Innate Immunity, 10.1161/circulationaha.106.670554
  39. Yajima T., Yasukawa H., Jeon E.-S., Xiong D., Dorner A., Iwatate M., Nara M., Zhou H., Summers-Torres D., Hoshijima M., Chien K. R., Yoshimura A., Knowlton K. U., Innate Defense Mechanism Against Virus Infection Within the Cardiac Myocyte Requiring gp130-STAT3 Signaling, 10.1161/circulationaha.106.642454
  40. Kindermann I., Kindermann M., Kandolf R., Klingel K., Bultmann B., Muller T., Lindinger A., Bohm M., Predictors of Outcome in Patients With Suspected Myocarditis, 10.1161/circulationaha.108.769489
  41. Badorff Cornel, Lee Gil-Hwan, Knowlton Kirk U., Enteroviral Cardiomyopathy: Bad News for the Dystrophin-Glycoprotein Complex, 10.1007/s000590050011
  42. Lee, Circ Res, 87, 489 (2000)
  43. Cooper L. T., Baughman K. L., Feldman A. M., Frustaci A., Jessup M., Kuhl U., Levine G. N., Narula J., Starling R. C., Towbin J., Virmani R., , The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology, 10.1161/circulationaha.107.186093
  44. Hunt Sharon A, Baker David W, Chin Marshall H, Cinquegrani Michael P, Feldman Arthur M, Francis Gary S, Ganiats Theodore G, Goldstein Sidney, Gregoratos Gabriel, Jessup Mariell L, Noble R.Joseph, Packer Milton, Silver Marc A, Stevenson Lynne Warner, Gibbons Raymond J, Antman Elliott M, Alpert Joseph S, Faxon David P, Fuster Valentin, Gregoratos Gabriel, Jacobs Alice K, Hiratzka Loren F, Russell Richard O, Smith Sidney C, ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary, 10.1016/s0735-1097(01)01683-7
  45. Cave Alison C., Brewer Alison C., Narayanapanicker Anilkumar, Ray Robin, Grieve David J., Walker Simon, Shah Ajay M., NADPH Oxidases in Cardiovascular Health and Disease, 10.1089/ars.2006.8.691
  46. Hein S., Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human Heart: Structural Deterioration and Compensatory Mechanisms, 10.1161/01.cir.0000051865.66123.b7
  47. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., Imaizumi T., Hypertensive Myocardial Fibrosis and Diastolic Dysfunction: Another Model of Inflammation?, 10.1161/01.hyp.0000118584.33350.7d
  48. Ammarguellat F. Z., Gannon P. O., Amiri F., Schiffrin E. L., Fibrosis, Matrix Metalloproteinases, and Inflammation in the Heart of DOCA-Salt Hypertensive Rats: Role of ETA Receptors, 10.1161/hy0202.103481
  49. Nicoletti A, Cardiac fibrosis and inflammation interaction with hemodynamic and hormonal factors, 10.1016/s0008-6363(98)00305-8
  50. Vanderheyden M, Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy, 10.1136/hrt.2004.035733
  51. Seddon M., Looi Y. H, Shah A. M, Oxidative stress and redox signalling in cardiac hypertrophy and heart failure, 10.1136/hrt.2005.068270
  52. Lehoux S., Pressure-Induced Matrix Metalloproteinase-9 Contributes to Early Hypertensive Remodeling, 10.1161/01.cir.0000115521.95662.7a
  53. Matsusaka H., Ide T., Matsushima S., Ikeuchi M., Kubota T., Sunagawa K., Kinugawa S., Tsutsui H., Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload, 10.1161/01.hyp.0000208840.30778.00
  54. Heymans, Am J Pathol, 166, 15 (2005)
  55. de Bold Adolfo J, Ma Kenneth K -Y, Zhang Ying, de Bold Mercedes L Kuroski, Bensimon Michael, Khoshbaten Ali, The physiological and pathophysiological modulation of the endocrine function of the heart, 10.1139/y01-038
  56. Yudkin John S, Eringa Etto, Stehouwer Coen DA, “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease, 10.1016/s0140-6736(05)66585-3
  57. Frisbee Jefferson C., Vascular Dysfunction in Obesity and Insulin Resistance, 10.1080/10739680701296705
  58. Kurukulasuriya L Romayne, Govindarajan Gurushankar, Sowers James, Stroke prevention in diabetes and obesity, 10.1586/14779072.4.4.487
  59. Katakam P. V. G., Jordan J. E., Snipes J. A., Tulbert C. D., Miller A. W., Busija D. W., Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance, 10.1152/ajpregu.00520.2006
  60. Kawanami Daiji, Maemura Koji, Takeda Norihiko, Harada Tomohiro, Nojiri Takefumi, Imai Yasushi, Manabe Ichiro, Utsunomiya Kazunori, Nagai Ryozo, Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions, 10.1016/j.bbrc.2003.12.104
  61. Kumada M., Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages, 10.1161/01.cir.0000127953.98131.ed
  62. Takemura Yukihiro, Walsh Kenneth, Ouchi Noriyuki, Adiponectin and cardiovascular inflammatory responses, 10.1007/s11883-007-0025-4
  63. Tigno, Clin Hemorheol Microcirc, 29, 409 (2003)
  64. Rana J. S., Nieuwdorp M., Jukema J. W., Kastelein J. J. P., Cardiovascular metabolic syndrome ? an interplay of, obesity, inflammation, diabetes and coronary heart disease, 10.1111/j.1463-1326.2006.00594.x
  65. Singer Georg, Granger D. Neil, Inflammatory Responses Underlying the Microvascular Dysfunction Associated with Obesity and Insulin Resistance, 10.1080/10739680701283158
  66. Lügering Andreas, Schmidt Michael, Lügering Norbert, Pauels Hans-Gerd, Domschke Wolfram, Kucharzik Torsten, Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway, 10.1053/gast.2001.28702
  67. Kurrelmeyer K. M., Michael L. H., Baumgarten G., Taffet G. E., Peschon J. J., Sivasubramanian N., Entman M. L., Mann D. L., Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction, 10.1073/pnas.070036297
  68. Angelini A, Active versus borderline myocarditis: clinicopathological correlates and prognostic implications, 10.1136/heart.87.3.210
  69. Nian M., Inflammatory Cytokines and Postmyocardial Infarction Remodeling, 10.1161/01.res.0000130526.20854.fa
  70. Torre-Amione Guillermo, Anker Stefan D, Bourge Robert C, Colucci Wilson S, Greenberg Barry H, Hildebrandt Per, Keren Andre, Motro Michael, Moyé Lemuel A, Otterstad Jan Erik, Pratt Craig M, Ponikowski Piotr, Rouleau Jean Lucien, Sestier Francois, Winkelmann Bernhard R, Young James B, Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial, 10.1016/s0140-6736(08)60134-8
  71. Voll Reinhard E., Herrmann Martin, Roth Edith A., Stach Christian, Kalden Joachim R., Girkontaite Irute, 10.1038/37022
  72. Maisch Bernhard, Hufnagel G�nther, K�lsch Susanne, Funck Rainer, Richter Annette, Rupp Heinz, Herzum Matthias, Pankuweit Sabine, Treatment of Inflammatory Dilated Cardiomyopathy and (Peri)Myocarditis with Immunosuppression and i.v. Immunoglobulins, 10.1007/s00059-004-2628-7
  73. Gullestad, Circulation, 103, 220 (2001)
  74. McNamara, Circulation, 95, 2476 (1997)
  75. McNamara, Circulation, 103, 2254 (2001)
  76. Dennert R., Crijns H. J., Heymans S., Acute viral myocarditis, 10.1093/eurheartj/ehn296
  77. Kuhl U., Interferon-  Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction, 10.1161/01.cir.0000072766.67150.51
  78. Keren A., Invited for Debate: Is Virus Persistence a Determinant for Disease Progression?, Chronic Viral and Inflammatory Cardiomyopathy ISBN:9783540239710 p.55-61, 10.1007/3-540-30822-9_4
  79. Caforio, Autoimmunity, 41, 35 (2008)
  80. Caforio A. L.P., Mahon N. G., Baig M. K., Tona F., Murphy R. T., Elliott P. M., McKenna W. J., Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives, 10.1161/circulationaha.106.641472
  81. Matsui Shinobu, Fu Michael L.X., Katsuda Shogo, Hayase Mitsuru, Yamaguchi Nobuo, Teraoka Kohei, Kurihara Takayuki, Takekoshi Noboru, Murakami Eiji, Hoebeke Johan, Hjalmarson Åke, Peptides Derived from Cardiovascular G-protein-coupled Receptors Induce Morphological Cardiomyopathic Changes in Immunized Rabbits, 10.1006/jmcc.1996.0307
  82. Jahns Roland, Boivin Valérie, Hein Lutz, Triebel Sven, Angermann Christiane E., Ertl Georg, Lohse Martin J., Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy, 10.1172/jci200420149
  83. Okazaki Taku, Tanaka Yoshimasa, Nishio Ryosuke, Mitsuiye Tamotsu, Mizoguchi Akira, Wang Jian, Ishida Masayoshi, Hiai Hiroshi, Matsumori Akira, Minato Nagahiro, Honjo Tasuku, Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice, 10.1038/nm955
  84. Dorffel, Circulation, 95, 1994 (1997)
  85. Mobini Reza, Staudt Alexander, Felix Stephan B., Baumann Gert, Wallukat Gert, Deinum Johanna, Svensson Helen, Hjalmarson Åke, Fu Michael, Hemodynamic improvement and removal of autoantibodies against β1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy, 10.1016/s0896-8411(03)00042-8
  86. Felix Stephan B, Staudt Alexander, Landsberger Martin, Grosse Yvonne, Stangl Verena, Spielhagen Thomas, Wallukat Gerd, Wernecke Klaus D, Baumann Gert, Stangl Karl, Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption, 10.1016/s0735-1097(01)01794-6
  87. Staudt Alexander, Hummel Astrid, Ruppert Jörg, Dörr Marcus, Trimpert Christiane, Birkenmeier Katrin, Krieg Thomas, Staudt Yvonne, Felix Stephan B., Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study, 10.1016/j.ahj.2006.06.027
  88. Staudt, Circulation, 103, 2681 (2001)
  89. Staudt Alexander, Staudt Yvonne, Dörr Marcus, Böhm Marco, Knebel Fabian, Hummel Astrid, Wunderle Lydia, Tiburcy Malte, Wernecke Klaus D., Baumann Gert, Felix Stephan B., Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy, 10.1016/j.jacc.2004.04.055
  90. Felix, Autoimmunity, 41, 484 (2008)
  91. Sawyer Douglas B., Siwik Deborah A., Xiao Lei, Pimentel David R., Singh Krishna, Colucci Wilson S., Role of Oxidative Stress in Myocardial Hypertrophy and Failure, 10.1006/jmcc.2002.1526
  92. Sirker Alexander, Zhang Min, Murdoch Colin, Shah Ajay M., Involvement of NADPH Oxidases in Cardiac Remodelling and Heart Failure, 10.1159/000109148
  93. Ide, Circ Res, 85, 357 (1999)
  94. Cappola T. P., Kass D. A., Nelson G. S., Berger R. D., Rosas G. O., Kobeissi Z. A., Marban E., Hare J. M., Allopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy, 10.1161/hc4501.098928
  95. Keith, Am J Clin Nutr, 73, 219 (2001)
  96. Cohn Jay N., Tam S. William, Anand Inder S., Taylor Anne L., Sabolinski Michael L., Worcel Manuel, Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT, 10.1016/j.cardfail.2007.03.001
  97. Hare Joshua M., Mangal Brian, Brown Joanne, Fisher Charles, Freudenberger Ronald, Colucci Wilson S., Mann Douglas L., Liu Peter, Givertz Michael M., Schwarz Richard P., Impact of Oxypurinol in Patients With Symptomatic Heart Failure, 10.1016/j.jacc.2008.01.068
  98. Garlanda Cecilia, Bottazzi Barbara, Bastone Antonio, Mantovani Alberto, PENTRAXINS AT THE CROSSROADS BETWEEN INNATE IMMUNITY, INFLAMMATION, MATRIX DEPOSITION, AND FEMALE FERTILITY, 10.1146/annurev.immunol.23.021704.115756
  99. Gustin C., Delaive E., Dieu M., Calay D., Raes M., Upregulation of Pentraxin-3 in Human Endothelial Cells After Lysophosphatidic Acid Exposure, 10.1161/atvbaha.107.158642
  100. Savchenko AS, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, Iwanari H, Sagara M, Tanaka T, Hamakubo T, Kodama T, Naito M, Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions, 10.1002/path.2314
  101. Latini R., Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction, 10.1161/01.cir.0000145167.30987.2e
  102. Salio M., Chimenti S., De Angelis N., Molla F., Maina V., Nebuloni M., Pasqualini F., Latini R., Garlanda C., Mantovani A., Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction, 10.1161/circulationaha.107.749234
  103. Rao R. M., Yang L., Garcia-Cardena G., Luscinskas F. W., Endothelial-Dependent Mechanisms of Leukocyte Recruitment to the Vascular Wall, 10.1161/circresaha.107.151860b
  104. Hirsch, Thromb Haemost, 95, 29 (2006)
  105. Camps, Nat Med, 11, 936 (2005)
  106. Crackower Michael A., Oudit Gavin Y., Kozieradzki Ivona, Sarao Renu, Sun Hui, Sasaki Takehiko, Hirsch Emilio, Suzuki Akira, Shioi Tetsuo, Irie-Sasaki Junko, Sah Rajan, Cheng Hai-Ying M., Rybin Vitalyi O., Lembo Giuseppe, Fratta Luigi, Oliveira-dos-Santos Antonio J., Benovic Jeffery L., Kahn C.Ronald, Izumo Seigo, Steinberg Susan F., Wymann Matthias P., Backx Peter H., Penninger Josef M., Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways, 10.1016/s0092-8674(02)00969-8
  107. Patrucco Enrico, Notte Antonella, Barberis Laura, Selvetella Giulio, Maffei Angelo, Brancaccio Mara, Marengo Stefano, Russo Giovanni, Azzolino Ornella, Rybalkin Sergei D., Silengo Lorenzo, Altruda Fiorella, Wetzker Reinhard, Wymann Matthias P., Lembo Giuseppe, Hirsch Emilio, PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects, 10.1016/j.cell.2004.07.017
  108. Doukas J., Wrasidlo W., Noronha G., Dneprovskaia E., Fine R., Weis S., Hood J., DeMaria A., Soll R., Cheresh D., Phosphoinositide 3-kinase  /  inhibition limits infarct size after myocardial ischemia/reperfusion injury, 10.1073/pnas.0606956103
  109. Weber KT Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation 1997 96
  110. Mann Douglas L., Basic mechanisms of disease progression in the failing heart: The role of excessive adrenergic drive, 10.1016/s0033-0620(98)80025-x
  111. Kurrelmeyer, Clin Cardiol, 21, I14 (1998)
  112. Janicki, Adv Exp Med Biol, 382, 239 (1995)
  113. Hudson Michael P., Armstrong Paul W., Ruzyllo Witold, Brum Jose, Cusmano Lisa, Krzeski Piotr, Lyon Robert, Quinones Miguel, Theroux Pierre, Sydlowski Diana, Kim Henry E., Garcia Mario J., Jaber Wael A., Weaver W. Douglas, Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction, 10.1016/j.jacc.2006.02.055
  114. White H, Applying the open artery theory: use of predictive survival markers, 10.1053/euhj.1998.1017
  115. Pfeffer MA Braunwald E Ventricular remodeling after myocardial infarction Experimental observations and clinical implications 1990
  116. VANHOUTTE D, SCHELLINGS M, PINTO Y, HEYMANS S, Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window, 10.1016/j.cardiores.2005.10.002
  117. Gullestad L., Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study, 10.1161/circulationaha.105.564971
  118. SCHELLINGS M, Matricellular proteins in the heart: possible role during stress and remodeling, 10.1016/j.cardiores.2004.06.006
  119. Trueblood N. A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., Jenkins A. W., Wang J., Sawyer D. B., Bing O. H. L., Apstein C. S., Colucci W. S., Singh K., Exaggerated Left Ventricular Dilation and Reduced Collagen Deposition After Myocardial Infarction in Mice Lacking Osteopontin, 10.1161/hh1001.090842
  120. Dobaczewski M., Bujak M., Zymek P., Ren G., Entman M. L., Frangogiannis N. G., Extracellular matrix remodeling in canine and mouse myocardial infarcts, 10.1007/s00441-005-0144-6
  121. Schroen B., Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy, 10.1161/01.res.0000141019.20332.3e
  122. Collins Alan R, Schnee Janet, Wang Wei, Kim Sarah, Fishbein Michael C, Bruemmer Dennis, Law Ronald E, Nicholas Susanne, Ross Robert S, Hsueh Willa A, Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart, 10.1016/j.jacc.2003.11.058
  123. Kühn Bernhard, del Monte Federica, Hajjar Roger J, Chang Yuh-Shin, Lebeche Djamel, Arab Shima, Keating Mark T, Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair, 10.1038/nm1619
  124. Shimazaki Masashi, Nakamura Kazuto, Kii Isao, Kashima Takeshi, Amizuka Norio, Li Minqi, Saito Mitsuru, Fukuda Keiichi, Nishiyama Takashi, Kitajima Satoshi, Saga Yumiko, Fukayama Masashi, Sata Masataka, Kudo Akira, Periostin is essential for cardiac healingafter acute myocardial infarction, 10.1084/jem.20071297
  125. Imanaka-Yoshida, Histol Histopathol, 19, 517 (2004)
  126. Tamaoki, Am J Pathol, 167, 71 (2005)
  127. Li Zhuqing, Calzada Maria J., Sipes John M., Cashel Jo Anne, Krutzsch Henry C., Annis Douglas S., Mosher Deane F., Roberts David D., Interactions of thrombospondins with α4β1 integrin and CD47 differentially modulate T cell behavior, 10.1083/jcb.200109098
  128. Calzada Maria J., Sipes John M., Krutzsch Henry C., Yurchenco Peter D., Annis Douglas S., Mosher Deane F., Roberts David D., Recognition of the N-terminal Modules of Thrombospondin-1 and Thrombospondin-2 by α6β1Integrin, 10.1074/jbc.m302014200
  129. Tremble, Mol Biol Cell, 5, 439 (1994)
  130. Brekken Rolf A., Sage E.Helene, SPARC, a matricellular protein: at the crossroads of cell–matrix communication, 10.1016/s0945-053x(00)00133-5
  131. Yang Zhantao, Strickland Dudley K., Bornstein Paul, Extracellular Matrix Metalloproteinase 2 Levels Are Regulated by the Low Density Lipoprotein-related Scavenger Receptor and Thrombospondin 2, 10.1074/jbc.m008925200
  132. Fischer, Br J Pharmacol, 153, S414 (2008)
  133. Hirota Hisao, Chen Ju, Betz Ulrich A.K, Rajewsky Klaus, Gu Yusu, Ross John, Müller Werner, Chien Kenneth R, Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress, 10.1016/s0092-8674(00)80729-1
  134. SCHAFRANSKI M. D., STIER A., NISIHARA R., MESSIAS-REASON I. J. T., Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: a beneficial role for MBL deficiency, 10.1111/j.1365-2249.2004.02645.x
  135. Collard C. D., Shernan S. K., Fox A. A., Bernig T., Chanock S. J., Vaughn W. K., Takahashi K., Ezekowitz A. B., Jarolim P., Body S. C., The MBL2 'LYQA Secretor' Haplotype Is an Independent Predictor of Postoperative Myocardial Infarction in Whites Undergoing Coronary Artery Bypass Graft Surgery, 10.1161/circulationaha.106.679530
  136. Saevarsdottir Saedis, Oskarsson Oskar Orn, Aspelund Thor, Eiriksdottir Gudny, Vikingsdottir Thora, Gudnason Vilmundur, Valdimarsson Helgi, Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk, 10.1084/jem.20041431
  137. Collard, Am J Pathol, 156, 1549 (2000)
  138. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen H O, Mannose-binding lectin and its genetic variants, 10.1038/sj.gene.6364283
  139. Ueland Thor, Espevik Terje, Kjekshus John, Gullestad Lars, Omland Torbjørn, Squire Iain B., Frøland Stig S., Mollnes Tom E., Dickstein Kenneth, Aukrust Pål, Mannose Binding Lectin and Soluble Toll-like Receptor 2 in Heart Failure Following Acute Myocardial Infarction, 10.1016/j.cardfail.2006.07.002
  140. Keller T. T., Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women, 10.1161/01.atv.0000240517.69201.77
  141. Troelsen Lone N., Garred Peter, Madsen Hans Ole, Jacobsen Søren, Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis, 10.1002/art.22302